CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation

Gastroenterology. 2005 Sep;129(3):913-27. doi: 10.1053/j.gastro.2005.06.061.

Abstract

Background & aims: Recently, we demonstrated a proinflammatory effect of cytosin-guanosin dinucleotide (CpG)-oligodeoxynucleotide (ODN) treatment in established dextran sulphate sodium (DSS)-induced colitis. Here, we investigated whether DNA derived from luminal bacteria plays a role in the perpetuation of chronic intestinal inflammation.

Methods: Toll-like receptor (TLR9)-deficient and wild-type (wt) control mice were used for the induction of chronic DSS colitis. Moreover, mice with established chronic colitis using different experimental models were treated with adenoviral ODN (AV-ODN) known to block CpG effects. Colonic inflammation was scored and cytokine production was quantified both in colonic tissue and draining mesenteral lymph node cells (MLC).

Results: Eight weeks after induction of chronic DSS colitis in TLR9-deficient mice, intestinal inflammation was significantly lower (-68%), and proinflammatory cytokine production was drastically reduced. Treatment of wt mice with chronic DSS-induced colitis with AV-ODN resulted in a significant amelioration of disease with a reduced histologic score (-43%) and reduced cytokine production of MLC (interleukin [IL]-6: -68%; interferon [IFN]-gamma: -48%) and RNA expression of the T helper (Th)1-specific transcription factor T-bet (-62%) in colonic tissue. Qualitatively, the same results were obtained in the severe combined immunodeficiency disease (SCID) transfer model of colitis and in spontaneous colitis in IL-10-deficient mice.

Conclusions: Bacterial DNA derived from luminal bacteria contributes significantly to the perpetuation of chronic intestinal inflammation. Inhibition of the immune-stimulating properties of bacterial DNA using AV-ODN may offer a novel and specific tool for the treatment of inflammatory bowel disease.

MeSH terms

  • Animals
  • Bacterial Infections / complications
  • Base Sequence
  • Colitis / drug therapy*
  • DNA Primers
  • DNA, Bacterial / chemistry*
  • DNA-Binding Proteins / deficiency
  • DNA-Binding Proteins / genetics
  • Dinucleoside Phosphates / analysis*
  • Dinucleoside Phosphates / therapeutic use*
  • Disease Models, Animal
  • Inflammation / genetics
  • Inflammation / prevention & control
  • Membrane Glycoproteins / deficiency
  • Membrane Glycoproteins / genetics
  • Mice
  • Mice, Knockout
  • Oligodeoxyribonucleotides / therapeutic use*
  • Receptors, Cell Surface / deficiency
  • Receptors, Cell Surface / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Toll-Like Receptor 7
  • Toll-Like Receptor 9

Substances

  • DNA Primers
  • DNA, Bacterial
  • DNA-Binding Proteins
  • Dinucleoside Phosphates
  • Membrane Glycoproteins
  • Oligodeoxyribonucleotides
  • Receptors, Cell Surface
  • Tlr7 protein, mouse
  • Tlr9 protein, mouse
  • Toll-Like Receptor 7
  • Toll-Like Receptor 9
  • cytidylyl-3'-5'-guanosine